Stefan W. Ryter

This paper identifies compartment- and cell-specific molecular programs in preclinical familial pulmonary fibrosis using multi-omic profiling and finds these signatures are partially represented in peripheral blood.

The paper uses single-cell transcriptomics to analyze an IPF cohort, revealing a transcriptional deficit refractory to current treatments and identifying STAT3 as a key regulator in the therapeutic gap.

This study shows that SB202190 activates PERK, which enhances TFEB activity and the autophagy-lysosomal pathway, reducing amyloidogenesis in neurodegenerative diseases.